Jiangxi Fushine Pharmaceutical Co., Ltd.

Total Valuation

Jiangxi Fushine Pharmaceutical Co., Ltd. carries a market capitalization of 11.16B, placing it among publicly traded companies globally. Its enterprise value stands at 6.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Jiangxi Fushine Pharmaceutical Co., Ltd. currently has 550.00M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 4.98, and the price-to-book ratio stands at 6.23.

Enterprise Valuation

Financial Position

Jiangxi Fushine Pharmaceutical Co., Ltd. maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.63, indicating elevated leverage, while an interest coverage ratio of -1.83 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Jiangxi Fushine Pharmaceutical Co., Ltd. has paid -6.44M in income taxes, reflecting an effective tax rate of 92.10.

Stock Price Statistics

Jiangxi Fushine Pharmaceutical Co., Ltd.'s stock has gained approximately 127.69231% over the past 52 weeks. The 50-day moving average sits at 18.11, while the 200-day moving average is 15.78.

Income Statement

Over the trailing twelve months, Jiangxi Fushine Pharmaceutical Co., Ltd. generated 1.01B in revenue and converted that into -256.55M in net income, yielding earnings per share of -0.47. EBITDA reached -72.65M, while operating income came in at -72.65M.

Balance Sheet

Jiangxi Fushine Pharmaceutical Co., Ltd. holds 608.69M in cash and equivalents against 1.68B in total debt, resulting in a net debt position of 815.36M. Total book value stands at 807.61M, with working capital of 229.06M providing operational flexibility.

Cash Flow

After subtracting -208.88M in capital expenditures, free cash flow totaled -208.88M - equivalent to -0.37 per share.

Margins

Jiangxi Fushine Pharmaceutical Co., Ltd. operates with a gross margin of 12.64, reflecting its pricing power and cost economics. The operating margin of -7.19 and net profit margin of -25.40 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -20.71 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Jiangxi Fushine Pharmaceutical Co., Ltd.'s most recent stock split took place on May 18, 2020 with a 5:8 split ratio.

Scores

Jiangxi Fushine Pharmaceutical Co., Ltd. posts an Altman Z-Score of 1.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.